Moderna Inc.’s stock erased early losses to gain more than 3% on Friday, after the biotech company posted a wider-than-expected fourth-quarter loss and offered soft guidance for 2025, offsetting ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

Despite negative financials, technical analysis indicates potential support at $28-30, justifying a "hold" position rather than a "sell.". Moderna (NASDAQ ... fall below its IPO price.

Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months. Moderna shares MRNA fell 2% in ...

Moderna, Inc. MRNA will release its fourth-quarter financial results, before the opening bell, on Friday, Feb. 14, 2025. Analysts expect the Cambridge, Massachusetts-based company to report a ...

Biotechnology company Moderna (NASDAQ:MRNA) met Wall Street’s revenue expectations in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other hand, the company’s full ...

Moderna posted a Q4 EPS loss of $(2.91), missing estimates, while revenue fell to $966M from $2.81B but beat the $942.8M consensus Moderna’s norovirus vaccine trial is on FDA hold due to a ...

(Bloomberg) -- Moderna Inc. recorded another quarterly loss as vaccine sales wane and the company had an unexpected charge for a canceled manufacturing contract. The Cambridge, Massachusetts-based ...